What's Happening?
Arsenal Medical has received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) for its RADIANT pivotal trial. This trial will evaluate NeoCast, a novel liquid embolic designed for use in treating chronic
subdural hematoma (cSDH) in conjunction with surgery. The RADIANT trial is a prospective, randomized, multicenter study that will compare NeoCast to Onyx LES, an existing FDA-approved embolic agent. The trial aims to enroll approximately 360 subjects across up to 35 sites in the United States and Australia. NeoCast is engineered to achieve predictable distal penetration of the middle meningeal artery while minimizing patient discomfort. The trial represents the first FDA-approved head-to-head study of two liquid embolic agents for cSDH.
Why It's Important?
The approval of the RADIANT trial is significant as it could lead to advancements in the treatment of chronic subdural hematoma, a common condition in neurointervention. NeoCast's development is part of a broader effort to provide innovative solutions that are simpler to use and better tolerated by patients compared to legacy materials. If successful, NeoCast could offer a new option for neurointerventionalists, potentially improving patient outcomes and reducing reliance on more cumbersome and less patient-friendly materials. This trial also highlights the ongoing innovation in medical devices aimed at addressing complex medical conditions.
What's Next?
With the FDA's IDE approval, Arsenal Medical will proceed with the RADIANT trial, enrolling participants and conducting the study across multiple sites. The trial's outcomes will be closely monitored by the medical community, as they could influence future treatment protocols for cSDH. The results of the trial will determine whether NeoCast can be a viable alternative to existing embolic agents, potentially leading to its wider adoption in clinical practice. Arsenal Medical will also continue to develop and refine NeoCast, with the aim of demonstrating its efficacy and safety in this pivotal trial.
